IHS Global Insight's latest multi-client study provides a comprehensive overview of the drug markets and associated regulations in BRIC-MT countries (Brazil, Russia, India, China, Mexico, and Turkey). Our primary research and market analysis helps organizations explore the opportunities for pharmaceutical and biotech firms in these markets.
Emerging markets are increasingly attractive to pharmaceutical companies, presenting strong opportunities for expansion and diversification; however, the challenging regulatory landscapes can pose investment risks.

In order to invest successfully, organizations need to develop greater insights into the emerging healthcare systems and regulatory environments within these markets.

**A NEW STUDY FROM IHS GLOBAL INSIGHT**

In our new multi-client study, *Maximizing Opportunities in the BRIC-MT Bloc: Market Access Strategies in the World’s Fastest Growing Markets*, we explore the opportunities presented by these pharmaceutical markets and delve into their regulatory environments.

Additionally, we examine the role of public and private healthcare insurers, and pricing and reimbursement policies for drugs developed in BRIC-MT countries.

*For each country the study answers key questions such as:*

- What are the business opportunities for the pharmaceutical industry? For which therapeutic areas?
- How is the statutory health insurance system organized?
- What are the procedures and timings for drug marketing approvals, as well as pricing and reimbursement?
- What is the best way to negotiate with relevant authorities?
- What are the time-to-market trends?
- What role does the private health sector play?
- What are the price trends for drugs in each country, including innovative drugs?

**METHODOLOGY**

Using primary and secondary research, the report provides in-depth insight into major emerging markets. It offers unique analysis based on detailed interviews with regulatory authorities, investigating their knowledge and perspectives on the market.

We encourage clients to review and provide input into the interview guidelines and the scope of the analysis to ensure we accommodate specific business needs. The report is supported by our healthcare and pharmaceutical team of experts and resources, providing a solid basis for analysis and forecasts.

Interview guidelines and other documents are drafted in English and then translated into the local language and reviewed by a professional translator. *Curriculum vitae* and the translated interview guides are made available to clients upon request.

**PRINCIPAL RESEARCH: A QUALITATIVE APPROACH USING IN-DEPTH INTERVIEWS**

- Telephone interviews of approximately 45 minutes
- Recorded interviews with the consent of the interviewee or written summary of the interview sent for final approval to the interviewee
- E-mail exchanges following the interview for further information

The telephone interviews are conducted by a qualified consultant and then reviewed by the IHS Global Insight project manager. A two-step process is implemented in order to avoid inconsistencies and maintain accurate results.

This report includes at least 15 interviews with regulatory authorities, investigating:

- The condition of the general healthcare system, with a focus on pricing and reimbursement policies
- The perception and condition of cost-containment policies for drug expenses
- The role of private health insurers and their impact on drug coverage
- Key therapeutic areas with unmet needs—hence, opportunities for drug development
- Expected trends and forecasts of pricing and reimbursement systems and healthcare market data

**SECONDARY RESEARCH**

- Extensive research based on secondary sources and data, analyzing market trends and opportunities in the BRIC-MT countries
- Sources include research materials from national authority institutions, such as the Brazilian National Drug Approval Agency, the Chinese Ministry of Health, the Indian National Pharmaceutical Pricing Authority, and the Mexican Social Security Institute
  - IHS Global Insight’s Pharmaceutical and Healthcare Group and national pharmaceutical newspapers, such as China Pharmaceutical News, or specialised Web sites, such as www.pharmabiz.com in India.
- Extensive analysis of legal and regulatory frameworks
- Highlights on the main stakeholders and healthcare market data